Latest Trials
Latest News
FAQ
Pharmaceutical Companies
Pharma Details
Peter Moosmann
🇩🇪
Germany
Country
🇩🇪
Germany
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News
Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL)
Phase 1
Completed
Conditions
Lymphoma, Non-Hodgkin
Interventions
Drug: Bendamustine
Drug: Bortezomib
Subscribe
First Posted Date
2007-01-25
Last Posted Date
2015-04-03
Lead Sponsor
Peter Moosmann
Target Recruit Count
12
Registration Number
NCT00426855
Subscribe
Prev
1
Next
© Copyright 2024. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy